Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics has reported Short term Debt over the past 7 years, most recently at $59.4 million for Q2 2025.

Quarterly Short term Debt changed N/A to $59.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Jun 2025, changed N/A year-over-year, with the annual reading at $3.1 million for FY2020, 8.82% down from the prior year.
Short term Debt was $59.4 million for Q2 2025 at Myriad Genetics, down from $104.1 million in the prior quarter.
Over five years, Short term Debt peaked at $104.1 million in Q2 2021 and troughed at $59.4 million in Q2 2025.